Post-radiotherapy Rhinosinusitis in Children (PRRSC)

University Hospital, Lille

Status: Not yet enrolling

Conditions: Chronic Sinusitis; Pediatric Cancer

Treatments: Other: SNOT 22 questionnaire

Study type: Observational

Funder types: Other

Identifiers

NCT05454163

2021_0549

2022-A00422-41 (Other Identifier)

Details and patient eligibility

About

Chronic rhinosinusitis (CRS) is a frequent complication of facial cancer treatment, mainly related to radiotherapy. However, while radiological involvement is frequent, clinical expression seems less important.

Few studies have investigated the incidence of this condition in the pediatric population while its evolution seems to be very chronic even if a partial improvement may occur with time.

Our objective is therefore to study the impact of CSR in children treated for cancer of the cervicofacial region, to evaluate its incidence and medium-term evolution in order to determine whether it is necessary to set up a specific follow-up in these patients.

The clinical impact of CSR is assessed by a specific SNOT 22 questionnaire in children treated for a head-neck mesenchymal malignancy in comparison with a control population consisting of children treated for a mesenchymal malignancy of non-head-neck location.

Enrollment: 55 estimated patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Study population: all patients under 18 years of age managed for a head neck mesenchymal cancer between January 1, 2018 and December 31, 2024
• Control population: all patient under 1 years of age managed for non -head neck mesenchymal cancer between January 1, 2018 and December 31, 2024

Exclusion criteria

• Patients with hematological tumors;
• Patients with mucociliary pathologies or proven allergic rhinitis before the diagnosis of cancer
• Patients who have required surgical treatment that has removed more than half of the sinus cavities
• Tumor recurrence at the time of inclusion
• Sinus surgery between the last radiological check-up and inclusion
• Administrative reasons: inability to receive informed information.

Trial design

55 participants in 2 patient groups

Exposed patients

Treatment:

Other: SNOT 22 questionnaire

Non exposed patients